following a full submission assessed under the orphan medicine process:
vorasidenib (Voranigo®) is accepted for use within NHSScotland.
Indication under review: for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and paediatric patients 12 years and older, who are not in need of immediate chemotherapy or radiotherapy following surgical intervention.
In a randomised, double-blind phase III study, vorasidenib significantly improved radiographic progression-free survival compared with placebo in patients with IDH-mutant Grade 2 astrocytoma or oligodendroglioma who were post-surgery and not in need of immediate chemotherapy or radiotherapy.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE)
Medicine details
- Medicine name:
- vorasidenib (Voranigo)
- SMC ID:
- SMC2844
- Indication:
For the treatment of grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and paediatric patients 12 years and older, who are not in need of immediate chemotherapy or radiotherapy following surgical intervention.
- Pharmaceutical company
- Servier Laboratories Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 March 2026